Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: Comparison with total therapy 2

British Journal of Haematology

Volumn 140, Issue 6, 2008, Pages 625-634

  Pineda Roman, Mauricio ^a   Zangari, Maurizio ^a   Haessler, Jeff ^b   Anaissie, Elias ^a   Tricot, Guido ^a   Van Rhee, Frits ^a   Crowley, John ^b   Shaughnessy Jr , John D ^a   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Bortezomib; Complete response; Myeloma; Prognosis; Total therapy

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; INTERFERON; MELPHALAN; THALIDOMIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL EVALUATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; GENE EXPRESSION PROFILING; HUMAN; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; TOTAL THERAPY 2 PROTOCOL; TOTAL THERAPY 3 PROTOCOL; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; EPIDEMIOLOGIC METHODS; FEMALE; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 39749085426     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06921.x     Document Type: Article

References (25)

1. Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.J., Grosbois, B. Bataille, R. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 349, 2495 2502.
2. Barlogie, B., Jagannath, S., Vesole, D., Tricot, G., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J. Crowley, J. (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 89, 789 793.
3. Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R. Crowley, J. (2004) Treatment of multiple myeloma. Blood, 103, 20 32.
4. Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M. Crowley, J. (2006a) Thalidomide and hematopoietic-cell transplantation in multiple myeloma. New England Journal of Medicine, 354, 1021 1030.
5. Barlogie, B., Tricot, G., van Rhee, F., Angtuaco, E., Walker, R., Epstein, J., Shaughnessy, J.D., Jagannath, S., Bolejack, V., Gurley, J., Hoering, A., Vesole, D., Desikan, R., Siegel, D., Mehta, J., Singhal, S., Munshi, N.C., Dhodapkar, M., Jenkins, B., Attal, M., Harousseau, J.L. Crowley, J. (2006b) Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. British Journal of Haematology, 135, 1365 2141.
6. Barlogie, B., Anaissie, E., van Rhee, F., Haessler, J., Hollmig, K., Pineda-Roman, M., Cottler-Fox, M., Mohiuddin, A., Alsayed, Y., Tricot, G., Bolejack, V., Zangari, M., Epstein, J., Petty, N., Steward, D., Jenkins, B., Gurley, J., Sullivan, E., Crowley, J. Shaughnessy, Jr., J.D. (2007) Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. British Journal of Haematology, 138, 176 185.
7. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. British Journal of Haematology, 102, 1115 1123.
8. Cox, D.R. (1972) Regression models and life-tables. Journal of the Royal Statistical Society, Series B, 34, 187 202.
9. Facon, T., Mary, J., Harousseau, J., Huguet, F., Berthou, C., Grosbois, B., Anglaret, B., Azzedine, A., Rodon, P., Peny, A. Intergroupe Francophone du Myélome 2006) Superiority of melphalan-prednisone (MP) + thalidomide)THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple Myeloma [abstract]. Journal of Clinical Oncology, 24, 18S.
10. Gooley, T.A., Leisenring, W., Crowley, J. Storer, B.E. (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine, 18, 695 706.
11. Kaplan, E.L. Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457 481.
12. Mateos, M.V., Hernandez, J.M., Hernandez, M.T., Gutierrez, N.C., Palomera, L., Fuertes, M., Diaz-Mediavilla, J., Lahuerta, J.J., de la Rubia, J., Terol, M.J., Sureda, A., Bargay, J., Ribas, P., de Arriba, F., Alegre, A., Oriol, A., Carrera, D., Garcia-Larana, J., Garcia-Sanz, R., Blade, J., Prosper, F., Mateo, G., Esseltine, D.L., van de Velde, H. San Miguel, J.F. (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood, 108, 2165 2172.
13. Moreau, P., Hullin, C., Garban, F., Yakoub-Agha, I., Benboubker, L., Attal, M., Marit, G., Fuzibet, J.G., Doyen, C., Voillat, L., Berthou, C., Ketterer, N., Casassus, P., Monconduit, M., Michallet, M., Najman, A., Sotto, J.J., Bataille, R. Harousseau, J.L. (2006) Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood, 107, 397 403.
14. Oakervee, H.E., Popat, R., Curry, N., Smith, P., Morris, C., Drake, M., Agrawal, S., Stec, J., Schenkein, D., Esseltine, D.L. Cavenagh, J.D. (2005) PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. British Journal of Haematology, 129, 755 762.
15. Orlowski, R.Z., Voorhees, P.M., Garcia, R.A., Hall, M.D., Kudrik, F.J., Allred, T., Johri, A.R., Jones, P.E., Ivanova, A., Van Deventer, H.W., Gabriel, D.A., Shea, T.C., Mitchell, B.S., Adams, J., Esseltine, D.L., Trehu, E.G., Green, M., Lehman, M.J., Natoli, S., Collins, J.M., Lindley, C.M. Dees, E.C. (2005) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 105, 3058 3065.
16. Orlowski, R.Z., Peterson, B.L., Sanford, B., Chanan-Khan, A.A., Zehngebot, L.M., Watson, P.R., Caligiuri, M.A., Larson, R.A. the Cancer Leukemia Group B 2006) Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with multiple myeloma: Cancer and Leukemia Group B study 10301. Blood, 108, 239a.
17. Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., Catalano, L., Zamagni, E., Petrucci, M.T., De Stefano, V., Ceccarelli, M., Ambrosini, M.T., Avonto, I., Falco, P., Ciccone, G., Liberati, A.M., Musto, P. Boccadoro, M. (2006a) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, 367, 825 831.
18. Palumbo, A., Falco, P., Falcone, A., Corradini, P., Di Raimondo, F., Giuliani, N., Rossi, G., Morabito, F., Canepa, L., Gozzetti, A., Ambrosini, M.T., Zeldis, J., Knight, R., Foà, R., Boccadoro, M. Petrucci, M.T. (2006b) Oral revlimid plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: results of a multicenter phase I/II study. Blood, 108, 240a.
19. Palumbo, A., Ambrosini, M.T., Benevolo, G., Pregno, P., Pescosta, N., Callea, V., Cangialosi, C., Caravita, T., Morabito, F., Musto, P., Bringhen, S., Falco, P., Avonto, I., Cavallo, F. Boccadoro, M. (2007) Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood, 109, 2767 2772.
20. Rajkumar, S.V., Hayman, S.R., Lacy, M.Q., Dispenzieri, A., Geyer, S.M., Kabat, B., Zeldenrust, S.R., Kumar, S., Greipp, P.R., Fonseca, R., Lust, J.A., Russell, S.J., Kyle, R.A., Witzig, T.E. Gertz, M.A. (2005) Combination therapy with lenalidomide plus dexamethasone (REV/DEX) for newly diagnosed myeloma. Blood, 106, 4050 4053.
21. Sawyer, J., Waldron, J., Jagannath, S. Barlogie, B. (1995) Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genetics and Cytogenetics, 82, 41 49.
22. Shaughnessy, Jr., J.D., Zhan, F., Burington, B.E., Huang, Y., Colla, S., Hanamura, I., Stewart, J.P., Kordsmeier, B., Randolph, C., Williams, D.R., Xiao, Y., Xu, H., Epstein, J., Anaissie, E., Krishna, S.G., Cottler-Fox, M., Hollmig, K., Mohiuddin, A., Pineda-Roman, M., Tricot, G., van Rhee, F., Sawyer, J., Alsayed, Y., Walker, R., Zangari, M., Crowley, J. Barlogie, B. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 109, 2276 2284.
23. Wang, M., Delasalle, K., Giralt, S. Alexanian, R. (2005) Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood, 106, 784a.
24. Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., Anaissie, E., Morris, C., Muwalla, F., van Rhee, F., Fassas, A., Crowley, J., Tricot, G., Barlogie, B. Shaughnessy, Jr., J. (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood, 99, 1745 1757.
25. Zhan, F., Huang, Y., Colla, S., Stewart, J.P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., Anaissie, E., Hollmig, K., Pineda-Roman, M., Tricot, G., van Rhee, F., Walker, R., Zangari, M., Crowley, J., Barlogie, B. Shaughnessy, Jr., J.D. (2006) The molecular classification of multiple myeloma. Blood, 108, 2020 2028.